CYAD - Celyad Oncology presents updates on shRNA-based CAR T programs at ASH meeting

Celyad Oncology (NASDAQ:CYAD) announces that data from the Phase 1 CYCLE-1 trial of CYAD-02 for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and the Phase 1 IMMUNICY-1 trial of CYAD-211 for the treatment of r/r multiple myeloma were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The data support the potential and versatility of non-gene edited short hairpin RNA (shRNA) technology for the development of next-generation CAR T therapies. CYAD-02 and CYCLE-1 Phase 1 Trial Update Data from CAR T candidate CYAD-02 using shRNA shows a single shRNA can target two independent genes to enhance the phenotype of the CAR T cells. A favorable tolerability profile for CYAD-02 with a low rate of Grade ? 3 cytokine release syndrome. Two MDS patients achieved a marrow complete response at dose level 3. Of the eight patients with stable

For further details see:

Celyad Oncology presents updates on shRNA-based CAR T programs at ASH meeting